Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
The present invention provides methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of amyloid-beta proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly those ocular diseases associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system.
1. A method for protection against, treating or alleviating one or more of the effects of an ocular disease associated with amyloid-beta-related pathological abnormalities or changes in the tissues of the visual system in a subject comprising administering intraocularly or intravitreally to the subject a pharmaceutical composition comprising an effective amount of an antibody which binds amyloid-beta, wherein the antibody comprises:
(i) a light chain variable region comprising a light chain complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 9, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and
(ii) a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 12, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 14,
and wherein the ocular disease is cortical visual deficits or cataract.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 2 , wherein the mammal is a human.
4. The method of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7.
5. The method of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
6. The method of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
7. The method of claim 1 , wherein the antibody is a monoclonal, chimeric, single chain, bispecific or bi-effective, simianized, or humanized antibody or an active fragment thereof.
8. The method of claim 1 , wherein the ocular disease is cataract.
9. The method of claim 1 , wherein the ocular disease is cortical visual deficits.